• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

联合局部化疗治疗侵袭性皮肤鳞状细胞癌。

Combination Topical Chemotherapy for the Treatment of an Invasive Cutaneous Squamous Cell Carcinoma.

出版信息

J Drugs Dermatol. 2020 Feb 1;19(2):202-204. doi: 10.36849/JDD.2020.2228.

DOI:10.36849/JDD.2020.2228
PMID:32155018
Abstract

Introduction: Standard of care for squamous cell carcinoma (SCC) is usually surgical, with either excision or Mohs micrographic surgery. However, surgery may not be ideal for elderly patients with numerous lesions, who are poor surgical candidates or who refuse surgery. Topical 5-fluorouracil (5-FU) and imiquimod have been studied off-label as monotherapies in the treatment of SCC in situ with promising results. However, long-term tumor-free survival rates are still less than with surgical management. Methods: We report a case of biopsy-proven invasive SCC in an 86-year-old Caucasian male with history of multiple actinic keratoses and no previous skin cancers. The patient declined surgical treatment due to concerns about cosmetic outcomes. A combination of topical 5% imiquimod cream, 2% 5-FU solution, and 0.1% tretinoin cream was used five nights per week under occlusion for a treatment goal of 30 total applications. The patient was evaluated in clinic every 2 weeks during which the site was treated with cryotherapy. The patient reported burning pain associated with treatment and only completed 24 of the 30 applications. Results: Follow-up biopsy 15 months after completing topical treatment revealed dermal scar with no evidence of residual carcinoma. Conclusion: Topical combination therapy with imiquimod, 5-FU, and tretinoin with intermittent, brief cryotherapy effectively treated a small, invasive SCC in this select patient who deferred surgery. Prospective randomized-controlled clinical trials to assess the role of combination topical treatment for invasive SCCs are warranted. J Drugs Dermatol. 2020;19(2)202-204. doi:10.36849/JDD.2020.2228

摘要

介绍

鳞状细胞癌(SCC)的标准治疗方法通常是手术,包括切除或莫氏显微外科手术。然而,对于有大量病变的老年患者、手术风险高的患者或拒绝手术的患者,手术可能不是理想的选择。外用 5-氟尿嘧啶(5-FU)和咪喹莫特已被研究作为原位 SCC 的单一疗法,结果有一定前景。然而,无瘤生存的长期比率仍低于手术治疗。

方法

我们报告了一例 86 岁白人男性的活检证实的浸润性 SCC,该患者有多个光化性角化病病史,无既往皮肤癌。由于担心美容效果,患者拒绝手术治疗。该患者使用外用 5%咪喹莫特乳膏、2%5-FU 溶液和 0.1%维甲酸乳膏,每周 5 晚封包,共 30 次。患者每 2 周在诊所接受评估,每次治疗时都使用冷冻疗法。患者报告与治疗相关的灼痛,仅完成了 30 次治疗中的 24 次。

结果

完成外用治疗 15 个月后进行的活检显示真皮瘢痕,无癌残留证据。

结论

对于选择不手术的患者,咪喹莫特、5-FU 和维甲酸联合外用治疗,并间歇性使用短暂冷冻疗法可有效治疗小面积侵袭性 SCC。需要进行前瞻性随机对照临床试验来评估联合外用治疗侵袭性 SCC 的作用。J 皮肤病学杂志。2020;19(2)202-204。doi:10.36849/JDD.2020.2228

相似文献

1
Combination Topical Chemotherapy for the Treatment of an Invasive Cutaneous Squamous Cell Carcinoma.联合局部化疗治疗侵袭性皮肤鳞状细胞癌。
J Drugs Dermatol. 2020 Feb 1;19(2):202-204. doi: 10.36849/JDD.2020.2228.
2
A Non-Surgical and Cost-Effective Treatment Approach Employing Topical Imiquimod, 5-Fluorouracil, and Tretinoin for Primary Non-Melanoma Skin Cancers.采用局部咪喹莫特、5-氟尿嘧啶和维 A 酸治疗原发性非黑素瘤皮肤癌的非手术、具有成本效益的治疗方法。
J Drugs Dermatol. 2021 Mar 1;20(3):260-267. doi: 10.36849/JDD.5427.
3
Assessing outcomes of topical 5-fluorouracil as primary and adjuvant therapy for squamous cell carcinoma in-situ.评估局部 5-氟尿嘧啶作为原位鳞状细胞癌的主要和辅助治疗的结果。
Arch Dermatol Res. 2024 May 24;316(6):220. doi: 10.1007/s00403-024-02906-4.
4
Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.咪喹莫特局部治疗基底细胞癌和鳞状细胞癌:临床经验
Cutis. 2007 Mar;79(3):241-8.
5
Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy.接受5%咪喹莫特和5%氟尿嘧啶治疗的肾移植患者原位鳞状细胞癌(鲍温病)
Dermatol Surg. 2001 Jun;27(6):561-4. doi: 10.1046/j.1524-4725.2001.00149.x.
6
Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.咪喹莫特或氟尿嘧啶局部治疗基底细胞癌和鳞状细胞癌:一项系统评价
Arch Dermatol. 2009 Dec;145(12):1431-8. doi: 10.1001/archdermatol.2009.291.
7
Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy.对于局部单一疗法治疗失败的原位皮肤鳞状细胞癌患者,采用5-氟尿嘧啶乳膏和咪喹莫特乳膏进行局部联合治疗。
J Am Acad Dermatol. 2006 Dec;55(6):1092-4. doi: 10.1016/j.jaad.2006.06.031. Epub 2006 Sep 6.
8
Keratinocyte Carcinoma Chemoprevention With a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin.咪喹莫特、5-氟尿嘧啶和维 A 酸联合用于预防角化细胞癌。
J Drugs Dermatol. 2023 May 1;22(5):486-490. doi: 10.36849/JDD.7334.
9
Rate of Recurrence of Lentigo Maligna Treated With Off-Label Neoadjuvant Topical Imiquimod, 5%, Cream Prior to Conservatively Staged Excision.未经批准的外用咪喹莫特乳膏新辅助治疗后,局限性切除前痣样恶性黑色素瘤的复发率。
JAMA Dermatol. 2018 Aug 1;154(8):885-889. doi: 10.1001/jamadermatol.2018.0530.
10
Incidence of invasive squamous cell carcinomas in biopsy-proven squamous cell carcinomas in situ sent for Mohs micrographic surgery.在接受 Mohs 显微外科手术的活检证实为原位鳞状细胞癌的患者中,侵袭性鳞状细胞癌的发生率。
Dermatol Surg. 2012 Sep;38(9):1456-60. doi: 10.1111/j.1524-4725.2012.02507.x. Epub 2012 Jun 26.

引用本文的文献

1
Keratoacanthoma-Type Invasive Squamous Cell Carcinoma Managed Non-surgically With Topical Immunomodulators.采用局部免疫调节剂非手术治疗的角化棘皮瘤型浸润性鳞状细胞癌
Cureus. 2025 Jun 18;17(6):e86267. doi: 10.7759/cureus.86267. eCollection 2025 Jun.
2
Cancer-associated miRNAs and their therapeutic potential.癌症相关的微小RNA及其治疗潜力。
J Hum Genet. 2021 Sep;66(9):937-945. doi: 10.1038/s10038-021-00938-6. Epub 2021 Jun 4.
3
Improving the Efficacy of EGFR Inhibitors by Topical Treatment of Cutaneous Squamous Cell Carcinoma with Ointment.
通过用软膏局部治疗皮肤鳞状细胞癌提高表皮生长因子受体(EGFR)抑制剂的疗效
Mol Ther Oncolytics. 2020 Oct 22;19:294-307. doi: 10.1016/j.omto.2020.10.009. eCollection 2020 Dec 16.
4
Deciphering the Molecular Landscape of Cutaneous Squamous Cell Carcinoma for Better Diagnosis and Treatment.解析皮肤鳞状细胞癌的分子图谱以实现更好的诊断和治疗。
J Clin Med. 2020 Jul 14;9(7):2228. doi: 10.3390/jcm9072228.